Werewolf Therapeutics (NASDAQ:HOWL – Get Free Report)‘s stock had its “outperform” rating restated by stock analysts at Wedbush in a research report issued on Monday, RTT News reports. They presently have a $9.00 target price on the stock. Wedbush’s target price points to a potential upside of 50.50% from the company’s previous close. Other equities […]